progression. Translational changes of apoptotic proteins were determined with an antibody array. The preclinical characterization of PS121912 includes the determination of metabolic stability and CYP3A4 inhibition. Results PS121912 induced apoptosis in all four cancer cells, with HL-60 cells being the most sensitive. At submicromolar concentrations, PS121912 amplified the growth inhibition of cancer cells caused by 1,25-(OH) 2 D 3 without being antiproliferative by itself. A knockout study with VDR si-RNA confirmed the mediating role of VDR. VDR target genes induced by 1,25-(OH) 2 D 3 were down-regulated with the co-treatment of PS121912. This process was highly dependent on the recruitment of coregulators that in case of CYP24A1 was SRC2. The combination of PS121912 and 1,25-(OH) 2 D 3 reduced the presence of SRC2 and enriched the occupancy of corepressor NCoR at the promoter site. E2F transcription factors 1 and 4 were down-regulated in the presence of PS121912 and 1,25-(OH) 2 D 3 that in turn reduced the transcription levels of cyclin A and D, thus arresting HL-60 cells in the S or G2/M phase. In addition, proteins with hematopoietic functions such as cyclindependent kinase 6, histone deacetylase 9 and transforming growth factor beta 2 and 3 were down-regulated as well. Elevated levels of P21 and GADD45, in concert with cyclin D1, also mediated the antiproliferative response of HL-60 in the presence of 1,25-(OH) 2 D 3 and PS121912. Studies at higher concentration of P121912 identified a VDR-independent pathway of antiproliferation that included the enzymatic and transcriptional activation of caspase 3/7. Conclusion Overall, we conclude that PS121912 behaves like a VDR antagonist at low concentrations but interacts with more targets at higher concentrations leading to apoptosis mediated by caspase 3/7 activation. In addition, PS121912 showed an acceptable metabolic stability to enable in vivo cancer studies.
Introduction
The inhibition of cancer cell growth in the presence of 1,25-dihydroxyvitamin D 3 (1,25-(OH) 2 D 3 ) was shown as early as 1979 [1, 2] , and since then, many groups have reported similar antiproliferative effects of vitamin D receptor (VDR) ligands in vitro and in vivo. This was followed by the systematic genomic analysis of 1,25-(OH) 2 D 3 effects in cancer cells using microarrays, which was carried out using prostate, breast, colon, ovarian and skin cancer cells, as well as leukemia cells [3] [4] [5] [6] [7] [8] . VDR ligands, including the endogenous and most active ligand 1,25-dihydroxyvitamin D 3 (1,25(OH) 2 D 3 ), bind the VDR with high affinity and are responsible for the transcription of genes that regulate cell cycle, tumor growth, apoptosis and cell differentiation as well as calcium homeostasis [9, 10] . Human clinical studies with 1,25(OH) 2 D 3 and analogs are dose-limited because of hypercalcemia and hypercalciuria, which can cause psychosis, bone pain, calcification of soft tissue, coronary artery disease, and, in severe cases, coma and cardiac arrest [11, 12] . These side effects prompted the synthesis of thousands of 1,25(OH) 2 D 3 analogs to develop VDR ligands with lower calcemic activity. In clinical trials, two synthetic VDR ligands that were developed to treat cancer did not achieve an acceptable therapeutic ratio [13, 14] .
Recently, coregulator proteins (coactivators and corepressors) have been identified as transcriptional master regulators [15] . Among other functions, coregulators govern the activation and repression of VDR-mediated transcription depending on the gene, cell type, and VDR ligand [16] [17] [18] [19] . We and others have introduced new classes of VDR modulators that in contrast to VDR ligand antagonists, bind liganded VDR and inhibit the interactions with coregulators [20] [21] [22] [23] . The VDR ligand antagonists include the irreversible antagonist TEI-9647 [24] , 25-carboxylic esters (ZK168218 and ZK159222) [25] , 26-adamantly substituted antagonists (ADTT and analogs) [26] , 22-butyl-branched VDR ligands [27] and non-secosteroid compounds that destabilize the active form of VDR [28, 29] . Newer irreversible VDR-coregulator inhibitors based on the 3-indolylmethanamine scaffold have a unique ability to selectively and covalently interact with VDR at its coregulator binding site [23] . It was shown that the interaction between VDR and steroid receptor coactivator 2 (SRC2) was selectively inhibited by 3-indolylmethanamine PS121912 and that at higher concentration, PS121912 inhibited the growth of cancer cells. Herein, we present the effects of PS121912 that are mediated by VDR such as coregulator recruitment and regulation of transcription. In addition, VDR-independent effects at higher concentrations of PS121912 are presented. 
Materials and methods

Reagents
Cytotoxicity assays
Cancer cells were plated in quadruplicate in 384-well plates and treated with different concentrations of PS121912 followed by incubation for 18 h at 37 °C. CellTiter-Glo (Promega) was added to quantify the number of live cells by luminescence using a Tecan M1000 reader. Controls were 3-dibutylamino-1-(4-hexylphenyl)propan-1-one (positive) and DMSO (negative). Three independent experiments were performed in quadruplicate, and data were analyzed using nonlinear regression with variable slope (GraphPadPrism).
Cell Proliferation Assay
Cancer cells were plated in 96-well tissue culture plates. After 5 h, cells were treated with DMSO, 1,25(OH) 2 D 3 (20 or 100 nM) or PS121912 (0.5 or 2 µM) using 50H hydrophobic-coated pin tool (V&P Scientific). The number of viable cells was determined each day in triplicate (5 days max) using CellTiterGlo. DMSO was used as control to determine the normal growth. The percentage of living cells in comparison to DMSO (negative control) and 3-dibutylamino-1-(4-hexylphenyl)propan-1-one (positive control). Three independent experiments were performed in quadruplicate. For siRNA studies, cells were plated in six-well plates at 1.5 M cell/well and treated for 24 h with 300 µl of untreated DMEM containing 8 µl VDR siRNA (Santa Cruz Biotechnology, sc-106692) or control siRNA (Santa Cruz Biotechnology, sc-37007), Lipofectamine™ LTX (12.5 μl), and PLUS™ reagent (4.3 μl).
Apoptosis assay
Cancer cells were plated in quadruplicate in 384-well plates and treated with different concentrations of PS121912 followed by incubation for 18 h at 37 °C. Caspase-Glo 3/7 (Promega) was added to quantify the activity of caspase 3/7 by luminescence using a Tecan M1000 reader. Ketoconazole and DMSO were used as positive and negative control, respectively. Three independent experiments were performed in quadruplicate, and data were analyzed using nonlinear regression with variable slope (GraphPadPrism).
ChIP HL-60 cells were plated in 6-well plates at 2 M cells per well and treated with either DMSO (0.03 %) or inhibitor PS121912 (0.5 μM) in the presence or absence of 1,25(OH) 2 D 3 (20 nM) for 18 h. The DNA was prepared using an Imprint ChIP Kit (Sigma, CHP1) providing all internal controls. The antibodies used were VDR (Santa Cruz Biotechnology, sc-1008), GRIP-1 (SRC2) (Santa Cruz Biotechnology, sc-6094) and NCoR (Santa Cruz Biotechnology, sc-1609). The CYP24A1 promoter primers were FP 5′-AGCACACCCGGTGAACTC-3′ and RP 5′-TGGAAGGAGGATGGAGTCAG-3′. SYBR Green Jumpstart TAQ Ready Mix (Sigma, s4438) was used for RT-qPCR in conjunction with thermal cycling conditions of initial 50 °C for 10 min, 95 °C for 5 min, and 50 cycles of 95 °C for 10 s and 60 °C for 30 s. ΔΔC t method was used to determine the % DNA occupancy in respect of input (3 %). Standard errors of mean were calculated from two independent experiments performed in triplicate.
RT-qPCR
Cancer cells were incubated at 37 °C with either DMSO or inhibitor PS121912 (2 or 0.5 μM) in the presence or absence of 1,25(OH) 2 D 3 (20 or 100 nM) for 18 h in a six-well plate. The cells were harvested using 0.3 ml of 0.25 % Trypsin (Hyclone, #SH3023601) and added to DMEM or RPMI media (1 mL). The cell suspension was spun down for 3 min at 700 rpm to form a cell pellet, and the supernatant medium was carefully removed. The cell pellet was resuspended in 350 µL of RTL buffer (RNAeasy kit, Qiagen) with the addition of mercaptoethanol. The cells were lysed using a QIAshredder (Qiagen), and total RNA was isolated using the RNAeasy kit (Qiagen). A QuantiFast SYBR Green RT-PCR Kit (Qiagen) was used for the real time PCR following the manufacturer's recommendations. Primers used in these studies are as follows: GAPDH FP 5′-ACCACAGTCCATGCCATCAC-3′, GA PDH RP 5′-TCCACCACCCTGTTGCTGTA-3′; TRPV6 FP 5′-ATGGTGATGCGGCTCATCAGTG-3′, TRPV6 RP 5′-GTAGAAGTGGCCTAGCTCCTCG-3′, IGFBP3 FP 5′-CGCCAGCTCCAGGAAATG-3′, IGFBP3 RP 5′-GC ATGCCCTTTCTTGATGATG-3′; CYP24A1 FP 5′-CTTT GCTTCCTTTTCCCAGAAT-3′, CYP24A1 RP 5′-CGCC GTAGATGTCACCAGTC-3′; P21 FP 5′-GGAAGACCAT GTGGACCTGT-3′, P21 RP 5′-GGCGTTTGGAGTGG TAGAAA-3′, GADD45a FP 5′-GGAGAGCAGAAGAC CGAAA-3′, GADD45a RP 5′-TCACTGGAACCCATT GATC-3′. RT-qPCR was carried out on a Mastercycler (Eppendorf). The thermal cycling conditions were an initial 50 °C for 10 min, 95 °C for 5 min, and 50 cycles of 95 °C for 10 s and 60 °C for 30 s. ΔΔC t method was used to measure the fold change in gene expression of target genes. Standard errors of mean were calculated from two independent experiments performed in triplicate. In addition, a TaqMan array human cyclins and cell cycle regulation (Life, #4414123) was used for each treatment (n = 2). The RNA was isolated as described above, and RT-qPCR was carried out using Quantifast Probe RT-PCR Kit (Qiagen).
Antibody array
Apoptosis antibody array was performed using RayBio Human Apoptosis Antibody Array G Series (Cat no. AAH-APO-G1-8). HL-60 cells were plated in four-well plates and treated with DMSO, 1,25(OH) 2 D 3 (20 nM), and 1,25(OH) 2 D 3 (20 nM)/PS121912 (500 nM). Cells were incubated for 18 h. Cell lysate was collected using 1X Cell Lysis Buffer provided in RayBio Human Apoptosis Antibody Array kit. The glass chip was assembled as recommended by the manufacturer. Hundred microliter of blocking buffer was added to completely cover the array area followed by 30-min incubation. After decanting the blocking buffer, 100 µL of cell lysate solution was added and incubated for 18 h at 4 °C. After decanting the sample, the antibody array area was washed 2 times with washing buffer I and 2 times with washing buffer II. The array area was incubated with 70 µL biotin-conjugated antibodies for 2 h at room temperature. After washing with washing buffer I and II, 70 µL of HiLyte Plus-conjugated streptavidin was added and incubated 2 h at room temperature. After the washing steps, the antibody array chip was dissembled and scanned using a fluorescence imager (Molecular Imager FX, Bio-Rad). The blot intensity was quantified with "Quantity One" software. Immediately, 30 µL of cold methanol solution containing 10 µM of internal standard caffeine was added and centrifuged at 10,000 rpm for 2 min to quench the reaction. The ratio of caffeine and PS121912 was measured by HPLC, and % PS121912 remaining was calculated. By plotting the log of % remaining against the time interval, the linear slope (k) was determined. The metabolic rate (k*C 0 /C), half-life (log2/k) and internal clearance (V*k) were calculated as well. k is the slope, C 0 is the initial concentration of PS121912 (µM), C is the concentration of microsomes (mg/mL), and V is the volume of incubation (µL)/protein in the incubation (mg). Data were presented as mean and standard error. Statistical significance was analyzed by Student's t test using the GraphPad Prism software (version 4.0). P value smaller than 0.01 (P < 0.01) were considered significant.
P450 inhibition assay
The CYP3A4 inhibition assay was performed using Vivid ® CYP3A4 Green Screening kit (Cat no. P2857) using the manufacturer's suggested protocol. First, the Master PreMix was prepared by diluting P450 BACULOSOMES Plus Reagent (50 µL) and 100X Vivid Regeneration System (100 µL) in 4,850 µL of 1X Vivid CYPP450 Reaction Buffer. Fifty microliter of Pre-Mix mixture and 40 µL of 1X Vivid CYPP450 Reaction Buffer were added into each well of 96-well plate. Using 50H hydrophobic-coated pin tool (V&P Scientific), PS121912 was added serial-diluted into the 96-well plate followed by a 10-min incubation period. During this incubation period, a 10X mixture of Vivid Substrate DBOMF and Vivid NADP + mixture were prepared as suggested by the manufacturer. The reaction was initiated by adding 10 µL of the 10X Vivid substrate and NADP mixture. The plate was incubated for 30 min, and fluorescence was measured using an excitation/emission wavelength of 550/590, respectively. DMSO was used as a negative control, and ketoconazole was used as a positive control to measure the activity of CYP3A4. Each concentration was measured in triplet with two independent measurements. IC 50 values were determined by nonlinear regression using GraphPadPrism.
Results
We investigated the acute cytotoxic effect of PS121912 with a panel of cancer cells consisting of DU145 (prostate), Caco2 (colon), HL-60 (monocytes) and SKOV3 (ovary) (Fig. B) . The cell viability was determined in the presence of PS121912 after 18 h. The results are depicted in Fig. 1c .
The cancer cell lines exhibited different sensitivities toward PS121912. Whereas DU145 cells showed little cell death at 100 μM PS121912, all other cells were not viable at that concentration. In contrast, HL-60 was the most sensitive cancer cell line with an LD 50 value of 6.8 ± 1.5 μM for PS121912. SKOV3 and Caco2 exhibited the same intermediate sensitivity toward PS121912. The distinction between necrosis and possible apoptosis as a mechanism of cell death was determined by quantifying the activity of caspase 3/7 [30] . PS121912 activated the executioner caspases with an EC 50 of 4.7 ± 2.3 μM. The inversely proportional relationship between cell death and activation of Fig. 1 Effects of PS121912 in DU145 (prostate), Caco2 (colon), HL-60 (monocytes) and SKOV3 (ovarian). a Chemical structure of PS121912; b induction of apoptosis after 18 h by PS121912 for different cancer cells. The initiation of apoptosis was determined by quantifying the activity of caspase 3/7 using a luminescence-based assay (Caspase-Glo 3/7, Promega); c determination of cell viability after 18 h assessed by quantification of cellular ATP using a luminescence-based assay (CellTiter-Glo, Promega). Three independent experiments were performed in quadruplicate for each doseresponse, and the data were analyzed by nonlinear regression using GraphPad Prism caspase 3/7 is indicative of apoptotic cell death of HL-60 cells in the presence of PS121912. At higher concentrations, the activation of caspase 3/7 was also observed for other cancer cells in accordance with a weaker toxicity observed for these cells.
PS121912 was developed as a selective and potent VDR-coregulator inhibitor to modulate VDR-mediated transcription in the presence of 1,25(OH) 2 D 3 [23] . At high concentrations, 1,25(OH) 2 D 3 itself induces anti-proliferation, which was studied in concert with PS121912 for four different cancer cell lines (Fig. 2) .
In contrast to DU145 and HL-60, 100 nM 1,25(OH) 2 D 3 had a minor antiproliferative effect in SKOV3 and Caco2 cells. The concentration of PS121912 was selected at such that minimal antiproliferative effects were observed in the absence of 1,25(OH) 2 D 3 . This approach was designed to identify effects of PS121912 that depend on the presence of 1,25(OH) 2 D 3 . Different PS121912 concentrations were tested with various cancer cells, and a non-antiproliferative concentration of 2 µM PS121912 was determined for DU145, Caco2 and SKOV3 (Fig. 2a-c) . For the more sensitive HL-60 cells, a PS121912 concentration of 500 nM was low enough to not cause any antiproliferation (Fig. 2d) . Importantly, when cancer cells were treated with a combination of 1,25(OH) 2 D 3 and PS121912, a significantly reduced viability was observed after 5 days for Caco2 cells in comparison with the sole treatment of 1,25(OH) 2 D 3 . A similar but less pronounced effect was observed for all other cancer cell lines. Furthermore, HL-60 that was transfected with VDR siRNA before compound treatment did not show inhibition of cell growth at the same concentrations (Fig. 2f) . Control siRNA-transfected cells behaved similar to non-transfected cells (Fig. 2d) , thus VDR a crucial mediator for the antiproliferative effects of 1,25(OH) 2 D 3 and the combination with PS121912.
It was shown that PS121912 inhibits the interaction between VDR and coactivator SRC2 in cells using a twohybrid assay [23] . In order to demonstrate the inhibition of DNA-bound VDR during transcription, a chromatin immunoprecipitation assay (ChIP) was carried out using specific antibodies for coactivator SRC2 and corepressor NCoR. The results are depicted in Fig. 3 .
1,25(OH) 2 D 3 induced the DNA occupancy of VDR at the CYP24A1 promoter site in addition to the recruitment of coactivator SRC2 (Fig. 3a, b) [31] . In respect of corepressor recruitment, 1,25(OH) 2 D 3 reduced the interaction between VDR and NCoR (Fig. 3c) . Importantly, the interaction between DNA-bound VDR and SRC2 was reduced in the presence of PS121912, whereas PS121912 promoted the interaction between VDR and NCoR. Finally, low concentrations of PS121912 by itself had no significant effect of the VDR-coregulator recruitment.
To determine the regulation of genes in the presence of 1,25(OH) 2 D 3 and PS121912, we measured the mRNA levels of direct VDR target genes bearing an identified VDR response element in their promoter sequence such as TRPV6 [32] , IGFBP3 [33] , CYP24A1 [34] , P21 [35] , GADD45 [36] . The results for four different cancer cells (DU145, Caco2, SKOV3, and HL-60) are summarized in Table 1 .
In general, many of the genes were up-regulated by 1,25(OH) 2 D 3, and this up-regulation was blocked with the co-treatment of 1,25(OH) 2 Tables 2 and 3 .
Overall, we observed a minor change in gene regulation with 500 nM PS121912 reflected by the absence of antiproliferation. TRPV6 is down-regulated in DU145, CYP24A1 is down-regulated in SKOV3 and HL-60, and P21 is downregulated in Caco2 cells. In comparison with Table 1 , PS121912 gene regulatory effects are highly dependent on the presence of 1,25(OH) 2 D 3 .
Furthermore, the expression levels of a large group of genes involved in cell cycle and proliferation were determined for HL-60 cells treated with 1,25(OH) 2 D 3 in the presence and absence of PS121912.
Among the 43 gene investigated, 12 genes were significantly down-regulated, which include cyclins A, D1, and D2, cyclin-dependent kinase 6, and cyclin-dependent kinase inhibitors 2A. In general, the effect was more pronounced for the combination treatment than the sole 1,25(OH) 2 D 3 treatment. In addition, transcription factors E2F-1 and E2F-4, glycogen synthase kinase 3 beta, histone deacetylase 6 and 9, and transforming growth factor beta 2 and 3 were down-regulated. In contrast, dual-specific phosphatase CDC25A and cyclin-dependent kinase 1A also known as P21 were up-regulated. An additional study with 20 nM 1,25(OH) 2 D 3 and 3 µM PS121912 was carried out resulting in similar gene regulation (results not shown).
The expression of proteins associated with apoptosis was examined using an antibody array. HL-60 cells were treated with DMSO, 1,25(OH) 2 D 3, or the combination of 1,25(OH) 2 D 3 and PS121912 for 18 h. Cell lysates were added to the array, which contains 44 apoptosis pull-down antibodies spotted in duplicate. Biotinylated antibodies were used for detection, which in turn were visualized with fluorescently labeled streptavidin. The results are depicted in Fig. 4 .
Nine proteins could be detected in HL-60 cells treated with DMSO, with IGF-II and HSP60 being the most prominent pro-apoptotic proteins. The treatment with In addition, the levels of pro-apoptotic BIM were elevated with PS121912.
In order to assess the potential utility of PS121912 in vivo, we determined its metabolic stability. The results are summarized in Table 4 .
The clearance of PS121912 is very good with a half-life of almost 3 h. PS121912 inhibits the function of CYP3A4 at higher concentrations, which might contributes to its prolonged clearance. Overall, PS121912 is a predominately hydrophobic molecule with a small polar surface area and an elevated logP value.
Finally, we investigate the effect of higher PS121912 concentrations in HL-60 especially in respect of apoptosis as demonstrated in Fig. 1 . Therefore, mRNA levels of caspase 3 and 7 were determined for HL-60 cells treated with 3 µM PS121912 (Fig. 5) .
In the presence of 20 nM 1,25(OH) 2 D 3 , no change in caspase 3 and caspase 7 mRNA levels was observed. However, PS121912 induced the expression of both caspases at a concentration of 3 µM independently of the concentration of 1,25(OH) 2 D 3 . Furthermore, mRNA levels of CYP3A4 were not altered in the presence of 1,25(OH) 2 D 3, PS121912, or a combination thereof. [38] . Therefore, the down-regulation of CYP24A1 is an important anticancer action of PS121912 that occurs in the presence of 1,25-(OH) 2 D 3 .
Other VDR target genes such as P21 and GADD45 are up-regulated in HL-60 in the presence of 1,25-(OH) 2 D 3 and in combination with PS121912 and are is most likely to mediate their antiproliferative effects. Both gene products have been reported to arrest cells in the G1/S or G2/M phase [39, 40] . In addition, 1,25-(OH) 2 D 3 has been known to induce monocytic differentiation of HL-60 mediated by up-regulated P21 [41] . For both anti-proliferative treatments, detectable P21 protein levels were observed in HL-60 as well as increased levels pro-apoptotic serine protease HTRA. During growth arrest, elevated levels of p21 inhibit CDK4 phosphorylation of cyclin D1 [42] . Thus, reduction in the expression levels of cyclin D1, observed for the cotreatment of 1,25-(OH) 2 D 3 and PS121912, is expected to amplify this apoptotic pathway leading to a pronounced cell cycle arrest.
Cyclin A1, which is found in many leukemia cell lines [43] , is highly expressed during the S and G 2 /M phase and is affiliated with transcription factor E2F-1 and p21 [44] . All three genes are down-regulated in the presence of 1,25-(OH) 2 D 3 and PS121912 thus leading to cell cycle arrest under these conditions. Among the cyclindependent kinases (CDK), only CDK6 is down-regulated, which in turn is controlled by cyclin D1-3 [45] . CDK6 is important for hematopoietic functions and is essential for the sustaining proliferation [46] . Also HDAC 9 has hematopoietic functions and is down-regulated 1,25-(OH) 2 D 3 and PS121912 impairing the progression of the cell cycle. Transforming growth factors beta (TGF-beta) is an essential cytokines involved in growth and development [47] . In cancer cells, however, TGF-beta 1 is a negative growth regulator, whereas the function of TGF-beta 2 and 3 is less understood. The down-regulation of TGF-beta 2 and 3 in the presence of 1,25-(OH) 2 D 3 and PS121912 might be specific to promyelocytic cells mediating a distinct pathway of antiproliferation. Finally, GSK-3, which supports the progression of leukemia [48] , is down-regulated by 1,25-(OH) 2 D 3 and PS121912 making GSK-3 an important target for VDR modulators.
We can conclude that PS121912, especially at low concentrations, behaves like a VDR antagonist reversing transcriptional effects of 1,25-(OH) 2 D 3 when used as cotreatment. In addition, PS121912 as well as other VDR antagonists does not reverse the antiproliferative effect of 1,25-(OH) 2 D 3 [49] . However, at higher concentrations, PS121912 might interact with more biological targets especially those responsible for the activation of caspase 3/7. In particular, the up-regulation of CASP3 and CASP7, which has not been reported to be mediated by VDR, is unique to PS121912.
Finally, we determined the preclinical properties of PS121912 in order to investigate this compound in vivo. The analysis revealed that PS121912 is metabolically stable and can inhibit the metabolic enzyme CYP3A4 at higher concentrations. Thus, we believe that the bioavailability of PS121912 will be sufficient in order to determine its anti-cancer effects in vivo.
